Company / Accounts Receivable
Thermo Fisher Scientific Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$8.9B
FY2025
5-year range
$8.0B / $8.9B
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
#5 of 138
Health Care
What the data says
Among 138 Health Care companies, Thermo Fisher Scientific is in the top 4% for accounts receivable. Accounts Receivable has fluctuated over the past 10 years, ranging from $3.0B in FY2016 to $8.9B in FY2025.
Based on SEC 10-K filings.
$8.9B in FY2025 with a 5-year CAGR of +9.2%. Top quartile in the Health Care sector.
Improved from $8.2B to $8.9B over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +3.1%
- 5-Year CAGR
- +9.2%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 138This company $8.9B Sector average $1.3B
▼
+573.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +9.2%, indicating consistent growth.
- In FY2025, accounts receivable increased 8.7% year-over-year.
- Ranks #5 out of 138 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2016.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.9B | +8.7% |
| FY2024 | $8.2B | -0.4% |
| FY2023 | $8.2B | +1.3% |
| FY2022 | $8.1B | +1.7% |
| FY2021 | $8.0B | +38.9% |
| FY2020 | $5.7B | +32.0% |
| FY2019 | $4.3B | +12.3% |
| FY2018 | $3.9B | -0.2% |
| FY2017 | $3.9B | +27.2% |
| FY2016 | $3.0B | +19.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026